Clinical Trial Update: Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial comparing aprepitant to desloratadine for pruritus related to EGFR-TKI therapy in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Aprepitant (aprepitant)
• Desloratadine (desloratadine)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED